All Sides Of Biosimilar Naming Debate Resist WHO Plan To Tie Qualifiers To Sites

Biosimilar developers and drug innovators both oppose a component of a World Health Organization plan to distinguish among biologics by linking identifiers to the product's manufacturing site, saying site-specific biological qualifiers (BQs) could run counter to the plan's goal of harmonization. The issue is likely to come up when stakeholders meet with WHO later this month during the next round of International Nonproprietary Names (INN) consultation. WHO in July laid out a plan for biological qualifiers -- an alphabetic code...